UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued:
27 October 2021, London UK
GSK announces Dr Harry (Hal) C. Dietz MD to join the Board as
Non-Executive Director
Appointment further strengthens Board scientific capabilities,
including in genetics which is central to GSK's R&D
approach
GlaxoSmithKline plc (LSE/NYSE: GSK) has today announced that Dr
Harry (Hal) C. Dietz MD, Professor of Genetic Medicine at The Johns
Hopkins University School of Medicine in the United States, will
join the Board of the Company as a Non-Executive Director. He will
join the Board with effect from 1 January 2022.
Hal's appointment further strengthens the Board's scientific
capabilities, in line with the commitment to increase
biopharmaceutical and scientific expertise for new GSK through
Non-Executive Director appointments prior to the demerger of the
Consumer Healthcare business in mid-2022. Hal will
become the Board's third
designated Scientific and Medical Expert alongside Dr Jesse
Goodman, former Chief Scientist at the US FDA, and Dr Laurie
Glimcher, President and CEO of the Dana-Farber Cancer
Institute.
The appointment also builds on other
recent Non-Executive
Director appointments, including Charles (Charlie) Bancroft, former
Executive Vice President at Bristol Myers Squibb (BMS), and Dr Anne
Beal, former instructor in paediatrics at Harvard Medical School
and Massachusetts General Hospital, and Chief Patient Officer at
Sanofi.
On joining the Board, Hal will become a member of the Science
Committee which supports the Board in its oversight and scrutiny of
the Company's R&D strategy and annual performance targets. It
also provides technical assurance, particularly in relation to
potential R&D related transactions.
Hal brings extensive experience in the field of human genetics
which is central to GSK's approach to R&D. He is a former
President of the American Society of Human Genetics and is
recognised as the world's leading authority on a genetic disorder
known as Marfan Syndrome. He also brings experience in development
of novel therapies, through his role as Founder of and Scientific
Adviser to Blade Therapeutics, a biopharmaceutical company focused
on disease-modifying treatments for fibrotic and neurodegenerative
diseases. In total, Hal has authored 282 original publications in
peer-reviewed journals across his career.
Commenting on the appointment, Sir Jonathan Symonds, Chairman
of GSK said: "I am
delighted to welcome Hal to GSK. Innovation is at the heart of our
purpose and continuing to strengthen our R&D pipeline remains a
key long-term priority as we prepare for the demerger. Hal's
expertise in some of the most exciting areas of science,
particularly human genetics, means he is perfectly-placed to
provide the insight and challenge we need as GSK moves further into
developing next generation medicines and vaccines for
patients."
Notes
|
1.
|
The appointment of Dr Harry (Hal) Dietz was made by the
Board on the recommendation of the Nominations & Corporate
Governance Committee.
|
|
2.
|
The Board has determined that Dr Hal Dietz will be an
independent Non-Executive Director on appointment in accordance
with the UK Corporate Governance Code.
|
|
3.
|
Dr Hal Dietz will receive the standard basic fee for a
Non-Executive Director of £95,000 per annum. He will also
receive a further £30,000 in respect of his additional duties
as a Board Scientific and Medical Expert and a one-off fee of
£40,000 as the independent Chair of GSK's Human Genetics
Scientific Advisory Board.
Dr Hal Dietz will be required to invest at least 25% of his
fees in GSK shares that should be held until his retirement from
the Board.
|
|
4.
|
"Scientific
and Medical Expert" - The Board designates Non-Executive Directors
whose expertise or backgrounds as renowned medical scientists,
researchers, or physicians mean that they can bring scientific or
industry expertise to the Board's deliberations.
|
|
5.
|
Membership of other Committees will be determined in due
course.
|
|
6.
|
Dr Hal Dietz does not have a service contract. He has a letter
of appointment which may be viewed by contacting the Company
Secretary at the Company's registered office.
|
|
7.
|
There are no additional details to disclose in respect of Dr
Hal Dietz's appointment under Listing Rule
9.6.13R.
|
|
8.
|
From 1 January 2022 the Board of GSK will comprise:
|
|
|
Sir Jonathan Symonds
Emma
Walmsley
Iain
Mackay
Dr Hal Barron
Vindi Banga
Charles Bancroft
Dr Anne Beal
Dr Vivienne Cox
Dr Hal
Dietz
Lynn
Elsenhans
Dr Jesse Goodman
Dr Laurie Glimcher
Urs Rohner
|
Non-Executive Chairman
Chief Executive Officer
Chief Financial Officer
Chief Scientific Officer and President, R&D
Senior Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
|
Biography
Dr Hal Dietz is Victor A. McKusick Professor of Paediatrics,
Medicine, and Molecular Biology & Genetics in the Institute of
Genetic Medicine at The Johns Hopkins University School of Medicine
and an Investigator in the Howard Hughes Medical Institute. As a
physician scientist, he has dedicated his entire career to the care
and study of individuals with heritable connective tissue disorders
with primary perturbations of extracellular matrix homeostasis and
function. His lab has identified the genes for many of these
conditions, for which he uses model systems to elucidate disease
mechanisms.
Dr Dietz has received multiple prestigious awards including the
Curt Stern Award from the American Society of Human Genetics, the
Colonel Harland Sanders Lifetime Achievement Award in Medical
Genetics, the Taubman Prize for excellence in translational medical
science, the Harrington Prize from the American Society for
Clinical Investigation and the Harrington Discovery Institute, the
Pasarow Award in Cardiovascular Research, the InBev-Baillet Latour
Health Prize from the country of Belgium, and the Research
Achievement Award from the American Heart Association.
He is an inductee of the American Society for Clinical
Investigation, American Association for the Advancement of Science,
Association of American Physicians, National Academy of Medicine,
and National Academy of Sciences.
He is the founder and scientific advisor to Blade Therapeutics. He
is also the independent Chair of GSK's Human Genetics Scientific
Advisory Board and a former President of the American Society of
Human Genetics.
Dr Dietz completed his BS at Duke University and received his
MD from the SUNY Upstate School of Medicine. He completed a
paediatric residency and a cardiology fellowship at The Johns
Hopkins University before joining the faculty in 1992.
About GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media enquiries:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kristen Neese
|
+1 804 217 8147
|
(Philadelphia)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Analyst/Investor enquiries:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2020 and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: October
27, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024
